PMID- 32880876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210118
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 10
DP  - 2020 Oct
TI  - The Real-World Observational Prospective Study of Health Outcomes with 
      Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline 
      Patient-Reported Outcomes.
PG  - 2383-2399
LID - 10.1007/s13300-020-00908-9 [doi]
AB  - INTRODUCTION: Although patient-reported outcome (PRO) measures provide important 
      information beyond clinical data, studies that assess the PROs of type 2 diabetes 
      mellitus (T2DM) patients initiating injectable glucose-lowering medications in 
      routine clinical practice are limited. We describe the perspectives of patients 
      based on a diversified panel of generic and disease-specific PRO measures at the 
      time of enrollment (baseline) in the TROPHIES study. METHODS: TROPHIES is a 
      24-month prospective observational study performed in France, Germany, and Italy 
      in patients with T2DM who initiated their first injectable glucose-lowering 
      medication with once-weekly dulaglutide or once-daily liraglutide. To better 
      understand the perspectives of these patients regarding their overall health, 
      treatment satisfaction, and quality of life and work, the patients' responses to 
      the following questionnaires were collected at baseline before they initiated 
      treatment with dulaglutide or liraglutide: EQ-5D-5L (scale: 0-1), EQ-VAS (visual 
      analog scale: 0-100), Impact of Weight on Self-Perceptions Questionnaire (IW-SP; 
      scale: 0-100), Diabetes Treatment Satisfaction Questionnaire Status (DTSQs; 
      scale: 0-36), and Diabetes Productivity Measure (DPM; scale: 0-100). Analyses 
      were descriptive in nature, with higher scores reflecting better outcomes. 
      RESULTS: Data from patients at the time of enrollment were analyzed. At baseline, 
      patients initiating dulaglutide (N = 1130) or liraglutide (N = 1051) rated their 
      quality of life in terms of mean EQ-5D-5L index as 0.84 and 0.83, and in terms of 
      mean EQ-VAS as 67.5 and 67.5, respectively. The mean baseline scores in patients 
      initiating dulaglutide or liraglutide were 59.8 and 61.3 for IW-SP, 24.6 and 25.8 
      for DTSQs, 78.6 and 79.5 for DPM Life Productivity, and 87.5 and 86.8 for DPM 
      Work Productivity, respectively. CONCLUSION: The information from this varied 
      panel of PRO instruments collected at baseline complements clinical outcomes 
      data.
FAU - Boye, Kristina S
AU  - Boye KS
AD  - Eli Lilly and Company, Indianapolis, IN, USA. boye_kristina_secnik@lilly.com.
FAU - Sapin, Helene
AU  - Sapin H
AD  - Lilly France SAS, Neuilly-sur-Seine, France.
FAU - Garcia-Perez, Luis-Emilio
AU  - Garcia-Perez LE
AD  - Lilly S.A., Alcobendas, Madrid, Spain.
FAU - Rosilio, Myriam
AU  - Rosilio M
AD  - Lilly France SAS, Neuilly-sur-Seine, France.
FAU - Orsini Federici, Marco
AU  - Orsini Federici M
AD  - Eli Lilly and Company, Sesto Fiorentino, FI, Italy.
FAU - Heitmann, Elke
AU  - Heitmann E
AD  - Lilly Deutschland GmbH, Bad Homburg, Germany.
FAU - Jung, Heike
AU  - Jung H
AD  - Lilly Deutschland GmbH, Bad Homburg, Germany.
FAU - Aigner, Ulrich
AU  - Aigner U
AD  - Versdias GmbH, Sulzbach-Rosenberg, Germany.
FAU - Guerci, Bruno
AU  - Guerci B
AD  - University Hospital of Nancy, Vandoeuvre Les Nancy, France.
FAU - Giorgino, Francesco
AU  - Giorgino F
AD  - University of Bari Aldo Moro, Bari, Italy.
FAU - Norrbacka, Kirsi
AU  - Norrbacka K
AD  - Eli Lilly and Company, Helsinki, Finland.
LA  - eng
PT  - Journal Article
DEP - 20200903
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7509014
OTO - NOTNLM
OT  - Dulaglutide
OT  - Glucagon-like peptide 1 receptor agonists
OT  - Liraglutide
OT  - Patient-reported outcomes
OT  - Real-world study
OT  - Type 2 diabetes patients
EDAT- 2020/09/04 06:00
MHDA- 2020/09/04 06:01
PMCR- 2020/09/03
CRDT- 2020/09/04 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/09/04 06:00 [pubmed]
PHST- 2020/09/04 06:01 [medline]
PHST- 2020/09/04 06:00 [entrez]
PHST- 2020/09/03 00:00 [pmc-release]
AID - 10.1007/s13300-020-00908-9 [pii]
AID - 908 [pii]
AID - 10.1007/s13300-020-00908-9 [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 Oct;11(10):2383-2399. doi: 10.1007/s13300-020-00908-9. Epub 
      2020 Sep 3.